• Tim Chevassut, Beverley J Hunt, and Sue Pavord.
• Brighton and Sussex Medical School, Brighton, and consultant haematologist, University Hospitals Sussex NHS Foundation Trust, UK Sue.Pavord@ouh.nhs.uk.
• Clin Med (Lond). 2021 Nov 1; 21 (6): e600e602e600-e602.

AbstractThe COVID-19 pandemic has resulted in the development of highly effective vaccines that provide hope to the global community for reducing the spread of SARS-CoV-2 and limiting the mortality and morbidity caused by the disease. These vaccines have been produced using differing technologies, taken through clinical trials, and rolled out across the UK at unprecedented speed. However, the recent emergence of rare cases of life-threatening thrombosis in association with thrombocytopenia has threatened to derail one particular vaccine, the Oxford AstraZeneca ChAdOx1 vaccine, upon which many countries are dependent for their vaccination programmes. The story of how this situation has been managed in the UK at the height of the vaccine roll-out represents a remarkable collective endeavour on the part of the haematology community, working closely with other acute medical and surgical professionals within the NHS and the UK health regulatory bodies, to provide rapid expert guidance that has saved lives and helped keep the national vaccination programme on track.© Royal College of Physicians 2021. All rights reserved.

18 keywords...

hide…